#USA #Mequon #Scott Kelly #Vector Science #Dr. Dobranowski

Vector Science & Therapeutics Expands Board of Directors

Vector Science & Therapeutics Corporation, a notable player in the biotechnology space, has taken a significant step forward by announcing the appointment of two influential leaders to its Board of Directors. On May 6, 2026, the company revealed that Dr. Alexander Dobranowski and Scott Kelly have joined the board, aiming to enhance governance and strategic capabilities as the firm progresses toward the commercialization of its innovative biomechanical drug delivery platforms.

Introducing the New Board Members

Dr. Alexander Dobranowski

Dr. Alexander Dobranowski serves as the President, Director, and Co-Founder of HEALWELL AI, a prominent healthcare artificial intelligence company focused on preventative care. With over 15 years of clinical and healthcare technology experience, Dr. Dobranowski has a strong track record in leading multiple ventures that develop innovative AI-driven solutions to address complex healthcare issues. His appointment brings a critical dimension to Vector’s Board, notably in the realms of clinical medicine and health technology.

“Precision delivery of peptides and biologics represents one of the most consequential frontiers in modern therapeutics,” remarked Dr. Dobranowski. “The ability to steer therapeutic agents to a targeted site with consistency and control is transformational.”

With his extensive background, Dr. Dobranowski is poised to play an essential role in shaping the clinical and commercial strategies as Vector continues to introduce its vital technologies to healthcare providers and patients.

Scott Kelly

Scott Kelly joins the board with more than 22 years of capital markets experience, making him a valuable asset to Vector as a recently listed company on the TSXV. His background includes serving as a director and chief financial officer for public companies traded on the TSX Venture Exchange and the Canadian Securities Exchange. Mr. Kelly holds a Bachelor of Commerce from Royal Roads University, equipping him with the necessary tools to contribute effectively to the board.

“Vector Science is at an exciting inflection point as a newly listed company with a differentiated technology platform and a clear path to commercialization,” said Mr. Kelly. “I look forward to putting my capital markets experience to work.”

Mr. Kelly's expertise in public company governance and capital markets operations will be instrumental for Vector's foundation as it seeks to expand its investor base and execute its growth strategies.

Board Composition

The recent appointments enhance the existing board, which includes notable figures such as Chairman Tommy Thompson, Chief Executive Officer Bill Jackson, and Co-Founder Barry Hix. These leaders collectively bring a wealth of knowledge and experience, enabling Vector to strategically navigate the challenges of the biotechnology landscape.

“These appointments reflect the momentum we are building at Vector,” commented Bill Jackson, CEO of Vector. “With Dr. Dobranowski’s clinical and healthcare AI leadership and Mr. Kelly’s capital markets expertise now on our Board, Vector is exceptionally well positioned to execute on our commercialization strategy.”

About Vector Science & Therapeutics

Headquartered in Mequon, Wisconsin, Vector Science & Therapeutics is dedicated to the development of novel biomechanical devices and active localized drug delivery platforms. These advancements aim to equip clinicians with site-directed interventions where precision is paramount and systemic risks cannot be tolerated. The company's shares trade on the TSX Venture Exchange under the symbol PAIN. More information is available on their website at www.vectorscience.co.

Conclusion

As Vector Science & Therapeutics moves forward, the addition of Dr. Alexander Dobranowski and Scott Kelly to the Board of Directors bodes well for the company’s future. Their expertise and leadership will undoubtedly propel Vector in its mission to innovate and commercialize critical healthcare technology, ultimately benefiting clinicians and patients alike. By strengthening its governance framework, the company is poised to make significant strides in the biotechnology field.